Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis makes new bid in Pliva battle
The new offer from Actavis is worth 795 kuna per share compared with the 743 kuna per share offer currently on the table from US-based Barr. Before the
The new offer from Actavis is worth 795 kuna per share compared with the 743 kuna per share offer currently on the table from US-based Barr. Before the
Results were consistent with previously reported data, showing immune responses when the vaccine was used alone or in combination with a DNA primer vaccine. In a study of
The vaccine was well-tolerated and the subjects showed strong cell immunity responses that may be important for controlling HIV infection. The trial involved priming an immune response with
The agreement will allow Akorn to manufacture injectable products in finished dosage form for GeneraMedix, who will market these products under the GeneraMedix label. The agreement includes products
Under the extension, ImmunoGen will no longer be obligated to present new targets for antibody-based anticancer therapeutics to Sanofi-Aventis, enabling the company to use such targets in the
Ablvax is a therapeutic vaccine currently being evaluated as a treatment for patients with resistant chronic myeloid leukemia (CML). Under terms of the agreement, MolecularMD will perform molecular
A Norwegian court ruled in Ranbaxy’s favor in a case involving two patents on Lipitor in Norway. However, as Pfizer points out, Ranbaxy is still unable to produce
Fluoxetine capsules are indicated for the treatment of premenstrual dysphoric disorder (PMDD). The disorder causes severe depression, bad mood swings and tension before menstruation. Eli Lilly’s Sarafem pulvules
Specific financial terms of the transaction are confidential, however, both companies will share in resulting revenue. “We are very excited about working with Zylera, as our patents are
The phase I study is designed to investigate the safety and tolerability of a single dose of the drug in healthy volunteers. As a next step in the